Immunovant (IMO) to Report Topline Data from Two Phase 3 Thyroid Eye Disease Trials in 2026 First Half

Immunovant (IMO) will report topline results from two Phase 3 trials evaluating its lead therapy for thyroid eye disease on a date to be announced in the first half of 2026. The trials, IMAB301 and IMAB302, are assessing the drug’s efficacy and safety in reducing eyelid retraction and improving visual function. The company anticipates the data will support a potential New Drug Application in 2026.